Seroepidemiological Study Of P53 Protein And Antibodies In Different Group People

Objective This study was aimed to investigate the prevalence of serum p53 protein and p53-Abs in four groups of subjects using ELISA which were newly developed by p53 protein and hen anti-human p53 protein IgY.Methods The full-length sequence of p53 gene was amplified by PCR and inserted into the prokaryotic-expression plasmid pGEX-4T-l. The purified fusion protein was used to immune the hens and could produce large amount of IgY which can be prepared by employing the water dilution method. Subsequently, a specific indirect ELISA and a sandwich ELISA technique were developed and used to detect serum p53 protein and p53-Abs in four groups subjects.Results SDS-PAGE displayed that the molecular weight of the expressed fusion protein was about 80 000. The prepared anti-p53-IgY was able to recognize the p53 protein not other proteins including GST expressed by prokaryote cells. The newly developed ELISA technique can be used to detect serum p53 protein and p53-Abs. A total of 120 subjects were positive for serum p53 protein and 158 for p53-Abs. The serum p53 protein difference was statistically significant between benzene-exposed group (11.14%) and cancer group (4.22%), non-malignant disease group (2.63%) or healthy individuals (0.34%). The prevalence of p53-Abs in cancer group (14.59%) was higher than benign neoplasm (4.41%), exposed group (5.51%) and healthy individuals (1.02%). High positive rate were found in patients with ovarian cancer (41.67%), followed by nasopharyngeal cancer (33.33%), leukaemia (24.24%). Serum p53 protein and p53-Abs were also present in patients with hepatocirrhosis, chronic hepatitis B, chronic cholecystitis, colon polyps, chronic appendicitis, etc.Conclusion The detection of serum p53 antigen and antibodies by ELISA may represent a suitable nonincasive investigation in assessing the clinical implications and the level of occupationally exposure. Though its lack of sensitivity, serum p53 could be valuable because serological analysis is a simple and a low-cost assay with a good specificity. Therefore, serum p53 assessment can be used for tumor screening and for the monitoring of high-risk individuals.